|
【结 构 式】
|
【分子编号】33423 【品名】4-([[tert-butyl(dimethyl)silyl]oxy]methyl)phenylamine; 4-([[tert-butyl(dimethyl)silyl]oxy]methyl)aniline 【CA登记号】 |
【 分 子 式 】C13H23NOSi 【 分 子 量 】237.41726 【元素组成】C 65.77% H 9.76% N 5.9% O 6.74% Si 11.83% |
合成路线1
该中间体在本合成路线中的序号:(I)The condensation of 4-(tert-butyldimethylsilyloxymethyl)aniline (I) with 2-(acetoxy)benzoyl chloride (II) by means of TEA in dichloromethane gives the corresponding amide (III), which is oxidized with DMP in dichloromethane to yield the benzoquinone (IV). The reaction of (IV) with H2O2 and K2CO3 affords the epoxide (V), which is finally desilylated with HF and pyridine in THF to provide the target compound.

| 【1】 Nicolaou, K.C.; et al.; New synthetic technology for the construction of N-containing quinones and derivatives thereof: Total synthesis of epoxyquinomycin B. Angew Chem. Int Ed Engl 2001, 40, 1, 207. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 33423 | 4-([[tert-butyl(dimethyl)silyl]oxy]methyl)phenylamine; 4-([[tert-butyl(dimethyl)silyl]oxy]methyl)aniline | C13H23NOSi | 详情 | 详情 | |
| (II) | 16900 | 2-(chlorocarbonyl)phenyl acetate; Acetylsalicyloyl chloride | 5538-51-2 | C9H7ClO3 | 详情 | 详情 |
| (III) | 50221 | 2-[[4-([[tert-butyl(dimethyl)silyl]oxy]methyl)anilino]carbonyl]phenyl acetate | C22H29NO4Si | 详情 | 详情 | |
| (IV) | 50222 | 2-([[4-([[tert-butyl(dimethyl)silyl]oxy]methyl)-3,6-dioxo-1,4-cyclohexadien-1-yl]amino]carbonyl)phenyl acetate | C22H27NO6Si | 详情 | 详情 | |
| (V) | 50223 | N-[6-([[tert-butyl(dimethyl)silyl]oxy]methyl)-2,5-dioxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2-hydroxybenzamide | C20H25NO6Si | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号:(IX)Coupling of the carboxylic acid (III) with the O-protected 4-aminobenzylalcohol (IX) as above and subsequent deprotection of the tert-butyldimethylsilyl (TBDMS) group with 6N HCl in acetone gave the benzylalcohol (X), which was reacted with thionyl chloride in chloroform/cat. pyridine to provide the benzylchloride (XI). Treatment of (XI) with the tertiary amine (XII) in DMF yielded TAK-779.

| 【1】 Shiraishi, M.; Seto, M.; Aramaki, Y.; et al.; TAK-779, a small molecule CCR5 antagonist: Design, synthesis, and in vitro activity of anilide derivatives. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26 1999, San Francisco) 1999, Abst F911. |
| 【2】 Shiraishi, M.; Aramaki, Y.; Seto, M.; et al.; Discovery of small molecule CCR5 antagonists. 19th Symp Med Chem and 8th Annu Meet Div Med Chem Jpn (Nov 17-19, Tokyo) 1999, Abst 2P-06. |
| 【3】 Aramaki, Y.; Seto, M.; Shiraishi, M.; et al.; Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 2000, 43, 10, 2049. |
| 【4】 Kanzaki, N.; Shiraishi, M.; Fujino, M.; Nishimura, O.; Baba, M.; Lizawa, Y.; TAK-779. Drugs Fut 2000, 25, 3, 252. |
| 【5】 Kitayoshi, T.; Aramaki, Y.; Oda, T.; Honda, S.; Shiraishi, M. (Takeda Chemical Industries, Ltd.); Anilide deriv., production and use thereof. JP 1999263764; WO 9932468 . |
| 【6】 Kuroshima, K.; Kanzaki, N.; Nishimura, O.; Shiraishi, M.; Sawada, H.; Baba, M.; Aramaki, Y. (Takeda Chemical Industries, Ltd.); Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative. JP 2000128782; JP 2000128842; US 6096780; WO 9932100 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (III) | 31560 | 2-(4-methylphenyl)-6,7-dihydro-5H-benzo[a]cycloheptene-8-carboxylic acid | C19H18O2 | 详情 | 详情 | |
| (IX) | 33423 | 4-([[tert-butyl(dimethyl)silyl]oxy]methyl)phenylamine; 4-([[tert-butyl(dimethyl)silyl]oxy]methyl)aniline | C13H23NOSi | 详情 | 详情 | |
| (X) | 33424 | N-[4-(hydroxymethyl)phenyl]-2-(4-methylphenyl)-6,7-dihydro-5H-benzo[a]cycloheptene-8-carboxamide | C26H25NO2 | 详情 | 详情 | |
| (XI) | 33425 | N-[4-(chloromethyl)phenyl]-2-(4-methylphenyl)-6,7-dihydro-5H-benzo[a]cycloheptene-8-carboxamide | C26H24ClNO | 详情 | 详情 | |
| (XII) | 33426 | N,N-dimethyltetrahydro-2H-pyran-4-amine; N,N-dimethyl-N-tetrahydro-2H-pyran-4-ylamine | C7H15NO | 详情 | 详情 |